Delivery Order SPE2DB25D3018-SPE2DB25FUXZA
Award Date 7/15/25
Potential Completion Date 7/16/25
Potential Value $8.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price delivery order, valued at $3,770.00, represents a non-set-aside competitive award and is scheduled for completion by April 22, 2025. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,455.90 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. This firm fixed-price delivery order, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $52,706.28, is scheduled for completion by August 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The contract received no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic medication commonly used to treat rheumatoid arthritis, Crohn's disease, and other autoimmune conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,994.64 and an ultimate completion date of December 2, 2025. The contract is issued under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $15,740.52 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on November 13, 2025, with an ultimate completion date of November 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on November 18, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The order, valued at $2,387.94 with a firm fixed price structure, will be fulfilled from the contractor's Conshohocken, Pennsylvania facility and is scheduled for completion by November 19, 2025. This is a non-set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,643.55 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply fulfillment supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,117.42 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication used primarily to treat rheumatoid arthritis and other inflammatory conditions. The award was made on November 18, 2025, with an ultimate completion date of November 19, 2025, under firm fixed price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used primarily for treating rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order has a ceiling value of $2,598.96 and an ultimate completion date of August 20, 2025. The award was made without a set-aside designation, indicating it was awarded through open competition. The...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...